Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

Ripu D. Jindal, Anilkumar R Pillai, Sahebrao P. Mahadik, Kevin Eklund, Debra M. Montrose, Matcheri S. Keshavan

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Objective: Brain-derived neurotrophic factor (BDNF) is a key factor known to mediate neuronal proliferation, differentiation, survival and response to stress. Decreases in BDNF levels have been reported in schizophrenia, but studies in treatment naïve patients are few. Herein we report on serum BDNF levels in a series of patients with first-episode treatment naïve psychoses in comparison to age matched healthy controls. Method: Fasting serum BDNF levels were measured in 41 patients with treatment naive first episode psychosis (24 with schizophrenia, schizoaffective disorder or schizophreniform disorder, and 17 with non-schizophrenia psychotic disorders) and 41 age-matched healthy controls. Results: A three group analyses of covariance (ANCOVA) showed a diagnosis effect (p=.038) in which patients with schizophrenia had lesser serum BDNF levels than patient with non-schizophrenia psychosis, who in turn had lesser BDNF levels than matched healthy controls. Planned two-group ANCOVAs suggested that patients with schizophrenia had lower serum BDNF level than matched controls (p=.016), whereas patients with non-schizophrenia psychosis did not differ from controls. There were no age effects on BDNF, but there was a trend (p=.08) for a gender by group interaction with greater reductions in female patients with schizophrenia. The BDNF levels did not correlate with magnitude of smoking, body mass index, severity of positive and negative symptoms or overall functioning. Conclusions: Serum BDNF may be reduced at the onset of psychosis but its role in the pathogenesis of schizophrenia remains unclear. Elucidating the role of BDNF in schizophrenia and related psychotic disorders may provide an important therapeutic target. Further studies are also needed to examine if patients with schizophrenia have more pronounced reductions in BDNF than those with affective psychosis.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalSchizophrenia Research
Volume119
Issue number1-3
DOIs
StatePublished - Jun 1 2010

Fingerprint

Brain-Derived Neurotrophic Factor
Antipsychotic Agents
Schizophrenia
Psychotic Disorders
Serum
Psychotic Affective Disorders
Therapeutics
Fasting
Body Mass Index
Smoking

Keywords

  • BDNF
  • Neuroplasticity
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. / Jindal, Ripu D.; Pillai, Anilkumar R; Mahadik, Sahebrao P.; Eklund, Kevin; Montrose, Debra M.; Keshavan, Matcheri S.

In: Schizophrenia Research, Vol. 119, No. 1-3, 01.06.2010, p. 47-51.

Research output: Contribution to journalArticle

Jindal, RD, Pillai, AR, Mahadik, SP, Eklund, K, Montrose, DM & Keshavan, MS 2010, 'Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia', Schizophrenia Research, vol. 119, no. 1-3, pp. 47-51. https://doi.org/10.1016/j.schres.2009.12.035
Jindal, Ripu D. ; Pillai, Anilkumar R ; Mahadik, Sahebrao P. ; Eklund, Kevin ; Montrose, Debra M. ; Keshavan, Matcheri S. / Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. In: Schizophrenia Research. 2010 ; Vol. 119, No. 1-3. pp. 47-51.
@article{d4c0681c7bb7410ba08f22887ce5ee10,
title = "Decreased BDNF in patients with antipsychotic na{\"i}ve first episode schizophrenia",
abstract = "Objective: Brain-derived neurotrophic factor (BDNF) is a key factor known to mediate neuronal proliferation, differentiation, survival and response to stress. Decreases in BDNF levels have been reported in schizophrenia, but studies in treatment na{\"i}ve patients are few. Herein we report on serum BDNF levels in a series of patients with first-episode treatment na{\"i}ve psychoses in comparison to age matched healthy controls. Method: Fasting serum BDNF levels were measured in 41 patients with treatment naive first episode psychosis (24 with schizophrenia, schizoaffective disorder or schizophreniform disorder, and 17 with non-schizophrenia psychotic disorders) and 41 age-matched healthy controls. Results: A three group analyses of covariance (ANCOVA) showed a diagnosis effect (p=.038) in which patients with schizophrenia had lesser serum BDNF levels than patient with non-schizophrenia psychosis, who in turn had lesser BDNF levels than matched healthy controls. Planned two-group ANCOVAs suggested that patients with schizophrenia had lower serum BDNF level than matched controls (p=.016), whereas patients with non-schizophrenia psychosis did not differ from controls. There were no age effects on BDNF, but there was a trend (p=.08) for a gender by group interaction with greater reductions in female patients with schizophrenia. The BDNF levels did not correlate with magnitude of smoking, body mass index, severity of positive and negative symptoms or overall functioning. Conclusions: Serum BDNF may be reduced at the onset of psychosis but its role in the pathogenesis of schizophrenia remains unclear. Elucidating the role of BDNF in schizophrenia and related psychotic disorders may provide an important therapeutic target. Further studies are also needed to examine if patients with schizophrenia have more pronounced reductions in BDNF than those with affective psychosis.",
keywords = "BDNF, Neuroplasticity, Psychosis, Schizophrenia",
author = "Jindal, {Ripu D.} and Pillai, {Anilkumar R} and Mahadik, {Sahebrao P.} and Kevin Eklund and Montrose, {Debra M.} and Keshavan, {Matcheri S.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.schres.2009.12.035",
language = "English (US)",
volume = "119",
pages = "47--51",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

AU - Jindal, Ripu D.

AU - Pillai, Anilkumar R

AU - Mahadik, Sahebrao P.

AU - Eklund, Kevin

AU - Montrose, Debra M.

AU - Keshavan, Matcheri S.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objective: Brain-derived neurotrophic factor (BDNF) is a key factor known to mediate neuronal proliferation, differentiation, survival and response to stress. Decreases in BDNF levels have been reported in schizophrenia, but studies in treatment naïve patients are few. Herein we report on serum BDNF levels in a series of patients with first-episode treatment naïve psychoses in comparison to age matched healthy controls. Method: Fasting serum BDNF levels were measured in 41 patients with treatment naive first episode psychosis (24 with schizophrenia, schizoaffective disorder or schizophreniform disorder, and 17 with non-schizophrenia psychotic disorders) and 41 age-matched healthy controls. Results: A three group analyses of covariance (ANCOVA) showed a diagnosis effect (p=.038) in which patients with schizophrenia had lesser serum BDNF levels than patient with non-schizophrenia psychosis, who in turn had lesser BDNF levels than matched healthy controls. Planned two-group ANCOVAs suggested that patients with schizophrenia had lower serum BDNF level than matched controls (p=.016), whereas patients with non-schizophrenia psychosis did not differ from controls. There were no age effects on BDNF, but there was a trend (p=.08) for a gender by group interaction with greater reductions in female patients with schizophrenia. The BDNF levels did not correlate with magnitude of smoking, body mass index, severity of positive and negative symptoms or overall functioning. Conclusions: Serum BDNF may be reduced at the onset of psychosis but its role in the pathogenesis of schizophrenia remains unclear. Elucidating the role of BDNF in schizophrenia and related psychotic disorders may provide an important therapeutic target. Further studies are also needed to examine if patients with schizophrenia have more pronounced reductions in BDNF than those with affective psychosis.

AB - Objective: Brain-derived neurotrophic factor (BDNF) is a key factor known to mediate neuronal proliferation, differentiation, survival and response to stress. Decreases in BDNF levels have been reported in schizophrenia, but studies in treatment naïve patients are few. Herein we report on serum BDNF levels in a series of patients with first-episode treatment naïve psychoses in comparison to age matched healthy controls. Method: Fasting serum BDNF levels were measured in 41 patients with treatment naive first episode psychosis (24 with schizophrenia, schizoaffective disorder or schizophreniform disorder, and 17 with non-schizophrenia psychotic disorders) and 41 age-matched healthy controls. Results: A three group analyses of covariance (ANCOVA) showed a diagnosis effect (p=.038) in which patients with schizophrenia had lesser serum BDNF levels than patient with non-schizophrenia psychosis, who in turn had lesser BDNF levels than matched healthy controls. Planned two-group ANCOVAs suggested that patients with schizophrenia had lower serum BDNF level than matched controls (p=.016), whereas patients with non-schizophrenia psychosis did not differ from controls. There were no age effects on BDNF, but there was a trend (p=.08) for a gender by group interaction with greater reductions in female patients with schizophrenia. The BDNF levels did not correlate with magnitude of smoking, body mass index, severity of positive and negative symptoms or overall functioning. Conclusions: Serum BDNF may be reduced at the onset of psychosis but its role in the pathogenesis of schizophrenia remains unclear. Elucidating the role of BDNF in schizophrenia and related psychotic disorders may provide an important therapeutic target. Further studies are also needed to examine if patients with schizophrenia have more pronounced reductions in BDNF than those with affective psychosis.

KW - BDNF

KW - Neuroplasticity

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77952670145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952670145&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2009.12.035

DO - 10.1016/j.schres.2009.12.035

M3 - Article

C2 - 20096541

AN - SCOPUS:77952670145

VL - 119

SP - 47

EP - 51

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -